DisclosureWe earn commission on partner links; ranking is set by our evidence-based methodology — not advertisers. Read policy
Henry Meds offers compounded semaglutide and tirzepatide via subscription, including provider visits.
Cheap GLP-1 access, but real regulatory and quality caveats
Henry Meds is a legitimate US telehealth company (operating as Adonis Health Inc. since 2022) offering some of the lowest GLP-1 prices around by prescribing compounded semaglutide and tirzepatide rather than brand drugs. The active molecules are the same ones proven in major trials, and bundled pricing with no separate membership fee is genuinely attractive. The catch is that compounded GLP-1s are not FDA-approved, their legal footing narrowed sharply after the FDA declared the semaglutide and tirzepatide shortages resolved (tirzepatide in October 2024, semaglutide in February 2025), and the company has an F BBB rating tied to billing complaints plus an ongoing trademark/advertising lawsuit from Eli Lilly.
We may earn a commission if you buy through this link, at no extra cost to you. It never affects our score. How we make money
Independent third-party ratings, shown for context. Not affiliated with HealthVetted scoring.
Henry Meds (henrymeds.com) is a telehealth company that prescribes treatments for weight management, hormone therapy, and sexual health. Its weight-loss line is built around GLP-1 receptor agonists. Henry is not a drug manufacturer and not, by itself, a pharmacy — it is the connective layer between you, a state-licensed prescribing clinician, and a contracted compounding pharmacy that fills the order.
The process follows the standard telehealth weight-loss model, with one notable difference in clinical touchpoint:
Henry's defining commercial feature is its bundled, all-inclusive pricing: a single monthly payment covers the provider visit, the medication, supplies (needles, syringes, alcohol swabs), shipping, and ongoing care, with no separate membership fee. Cold-chain shipments typically arrive with insulated packaging and ice packs, and reviewers consistently note that Henry tends to include anti-nausea medication (ondansetron) proactively — a small but genuinely thoughtful detail given how common early GLP-1 nausea is.
Henry offers compounded semaglutide and compounded tirzepatide in both injectable and oral formats. The injectables are the closest analogs to the branded drugs and carry the strongest evidence base. The oral compounded versions are convenient but rest on far weaker ground — there is no FDA-approved oral tirzepatide, and FDA-approved oral semaglutide (Rybelsus) is dosed and absorbed very differently from a compounded troche or drop, so oral-compounded efficacy should not be assumed equivalent to the injectable trial data below.
Semaglutide is the active ingredient in Ozempic and Wegovy (Novo Nordisk); tirzepatide is the active ingredient in Mounjaro and Zepbound (Eli Lilly). A *compounded* version is a drug mixed by a pharmacy rather than mass-manufactured and approved as a finished product.
This is not a technicality. Compounded drugs are not FDA-approved and are not evaluated by the FDA for safety, effectiveness, or quality (FDA). The agency does not review the formulation, potency, or purity of a compounded GLP-1 before it reaches patients. Consequently, the clinical efficacy data below comes from the *branded* molecules — not from the specific product Henry ships — and equivalence is assumed, not proven.
Compounding pharmacies fall into two categories. 503A pharmacies compound patient-specific prescriptions under state board of pharmacy oversight. 503B outsourcing facilities produce larger batches under tighter, FDA-registered quality requirements. Most telehealth GLP-1 supply has historically run through 503A pharmacies, which operate under lighter manufacturing oversight than either a 503B facility or an FDA-approved manufacturer.
The molecules themselves are among the most effective anti-obesity medications ever studied — but the evidence comes from the brand-name drugs, not from compounded copies.
Semaglutide (STEP 1 trial, NEJM 2021). In a 68-week randomized trial of 1,961 adults with overweight or obesity (without diabetes), once-weekly semaglutide 2.4 mg produced a mean weight loss of 14.9% of body weight versus 2.4% with placebo (Wilding et al., *NEJM* 2021; PMID 33567185).
Tirzepatide (SURMOUNT-1 trial, NEJM 2022). In a 72-week trial of adults with obesity or overweight (without diabetes), once-weekly tirzepatide produced mean weight loss of 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, versus 3.1% with placebo (Jastreboff et al., *NEJM* 2022; PMID 35658024).
Head-to-head (SURMOUNT-5, NEJM 2025). The first major head-to-head trial randomized adults with obesity (without diabetes) to tirzepatide or semaglutide for 72 weeks. Tirzepatide produced a mean weight loss of 20.2% versus 13.7% for semaglutide (Aronne et al., *NEJM* 2025; PMID 40353578). The likely reason: tirzepatide is a dual GIP/GLP-1 receptor agonist, while semaglutide acts on GLP-1 alone.
The honest limitation: these results belong to FDA-approved Ozempic/Wegovy and Mounjaro/Zepbound. There are no large randomized trials proving that a given compounded product — especially an oral one — delivers identical potency, purity, or results. If a compounded injectable is correctly formulated with the same molecule at the same dose, comparable effects are reasonable to expect, but "reasonable to expect" is not "proven," and the FDA has documented real-world variability in compounded GLP-1 products.
GLP-1 receptor agonists mimic an incretin hormone the gut releases after eating. They (1) stimulate glucose-dependent insulin secretion, (2) suppress glucagon, (3) slow gastric emptying so you feel full longer, and (4) act on appetite centers in the hypothalamus to reduce hunger and food "noise." Tirzepatide adds activity at the GIP receptor, a second incretin pathway thought to contribute to its larger average weight-loss effect. The net result is reduced calorie intake driven by genuinely reduced appetite — not willpower.
Henry's pricing is bundled — the quoted monthly figure includes the visit, medication, supplies, and shipping — but it is also dose-dependent and partly hidden until intake, which is the single most important thing to understand before signing up.
Publicly reported figures (which shift over time and by promotion) generally fall in these ranges:
Two caveats matter enormously. First, introductory "from $XX" pricing reflects the lowest starting dose. GLP-1 dosing escalates substantially over the first several months, and Henry's cost typically rises at each dose step-up — by roughly $100 per step on injectables, per multiple reviews. The headline starter price is rarely what a patient pays at a maintenance dose. Second, much of the pricing is not visible until you begin the intake quiz or speak with a provider, which makes apples-to-apples comparison shopping harder than it should be. Budget for the maintenance-dose price, not the teaser.
For context, brand-name Wegovy and Zepbound carry list prices of roughly $1,000+/month before insurance — which is precisely why demand for compounded options exploded. But the cash-pay gap has narrowed sharply: as of late 2025, both manufacturers sell self-pay vials directly to patients (Eli Lilly's LillyDirect offers Zepbound vials at roughly $299–$449/month depending on dose; Novo Nordisk's NovoCare offers Wegovy at roughly $199–$399/month, and Wegovy pills around $149–$299), often paired with a telehealth prescription. For some doses these branded cash prices now overlap with — or even undercut — compounded injectable pricing, so a current LillyDirect/NovoCare quote is worth checking before assuming compounded is the cheaper route.
This is where Henry — and every compounded-GLP-1 telehealth service — requires real scrutiny, because the legal foundation of the entire model has shifted.
The shortage exception has ended. Compounding of "essentially a copy" of an FDA-approved drug is normally prohibited, but it was broadly permitted while the branded drugs were on the FDA shortage list. The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved on February 21, 2025 (FDA). Enforcement discretion for 503A pharmacies compounding semaglutide ended around April 22, 2025, and for 503B outsourcing facilities around May 22, 2025 (FDA). In short: the blanket legal basis for mass-compounding straight copies of these drugs is gone.
What's still legal — and the gray zone. Pharmacies may still compound a product that is *not* essentially a copy — for example, a different dose or a formulation altered for a documented clinical reason (such as an allergy to an inactive ingredient). Many telehealth platforms have pivoted to "personalized" formulations, oral routes, or combination products to stay inside this exception. Whether a given product genuinely qualifies, versus being a copy in disguise, is contested and is exactly what regulators and courts are now examining.
Henry-specific signals to weigh:
None of this means Henry is a scam — many patients report smooth experiences and good outcomes. It means the product category sits on legally shifting ground, supply could be disrupted by enforcement or litigation, and you are taking a non-FDA-reviewed medication. Those are material facts, not footnotes.
The side-effect profile of the molecules is well characterized from the branded trials. The most common effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal pain, usually worst during dose escalation and easing over time (FDA labeling for Wegovy and Zepbound). Slow titration and the included anti-nausea medication help.
Serious but rarer risks carry FDA labeling attention:
A risk specific to compounding is dosing error. The FDA has received reports of patients overdosing on compounded semaglutide because of confusion measuring doses from multi-dose vials and unfamiliar concentrations (FDA). Pre-filled, clearly labeled supplies and provider-guided titration reduce this risk, but it is real and is a reason the live-video visit option matters.
A reasonable fit if you: are a cash-pay patient who cannot access or afford brand-name GLP-1s through insurance; meet clinical criteria (BMI 30+, or 27+ with a comorbidity); value an all-inclusive monthly fee with no surprise add-ons; want a real video visit option rather than questionnaire-only prescribing; and understand and accept that you are taking a non-FDA-reviewed compounded medication.
You should skip Henry (or choose a brand-name route) if you: can get FDA-approved Wegovy/Zepbound covered by insurance — that is the gold standard and worth pursuing first; have a contraindication (personal/family history of medullary thyroid cancer or MEN 2, prior pancreatitis, pregnancy); want the regulatory certainty of an FDA-approved finished product; or are uncomfortable with a category facing active litigation and possible supply disruption. The oral compounded options in particular warrant skepticism, since their efficacy is the least supported by evidence.
Henry Meds is one of the more polished operators in the compounded-GLP-1 telehealth space: a genuinely all-inclusive monthly fee, careful cold-chain shipping, proactive anti-nausea support, and a real video-visit option that beats questionnaire-only prescribing. For a cash-pay patient who can't access branded GLP-1s, it's a credible, lower-cost route to the same molecules — with the GLP-1 evidence base (STEP 1, SURMOUNT-1, SURMOUNT-5) being among the strongest in modern obesity medicine.
But the core caveats are not optional reading. You would be taking a compounded drug the FDA has not reviewed, in a category whose legal foundation collapsed when the shortages ended in 2025, amid active Eli Lilly litigation that targets the very "personalized" framing Henry uses. Price creep with dose escalation and pre-intake pricing opacity make budgeting harder than the headline numbers suggest, and the oral formulations are the weakest-supported part of the lineup. The single most valuable step before signing up is to check whether your insurance will cover FDA-approved Wegovy or Zepbound — and to compare a current LillyDirect or NovoCare cash-pay quote, since manufacturer self-pay prices fell into the low hundreds per month for some doses in late 2025. If a branded route is affordable, that is the better path. If it isn't, Henry is a defensible choice among compounders, provided you go in with the maintenance-dose price, the regulatory risk, and the contraindications fully in view.
Henry Meds prescribes compounded versions of GLP-1 receptor agonists, primarily semaglutide (the molecule in Ozempic and Wegovy) and tirzepatide (in Mounjaro and Zepbound). These drugs mimic the gut hormone GLP-1 (tirzepatide also mimics GIP), which slows stomach emptying, signals fullness to the brain, and improves how the body regulates blood sugar and appetite. The result is reduced hunger, smaller portions, and weight loss. "Compounded" means a licensed pharmacy mixes the medication rather than it being a mass-produced, FDA-approved finished product; the FDA has warned that some compounders have used unapproved salt forms (such as semaglutide sodium or acetate) that differ from the base molecule in the approved drugs.
Active ingredient: Compounded Semaglutide / Tirzepatide
Henry Meds has not published its own clinical trials; efficacy is inferred from studies of the same active molecules. In the pivotal STEP 1 trial (NEJM 2021, 1,961 adults over 68 weeks), once-weekly 2.4 mg semaglutide produced a mean 14.9% reduction in body weight versus 2.4% with placebo, and 86.4% of participants lost at least 5% of their body weight. Tirzepatide produced even larger average losses in its SURMOUNT program. Important caveat: compounded products are not FDA-approved and are not tested for the same bioequivalence, and Henry Meds' lower-strength and oral/sublingual formulations lack the trial evidence that supports the brand injectables, so individual results may differ and could be lower than the trial figures.
A realistic timeline of what Henry Meds GLP-1 users typically experience. Individual results vary; this is educational, not medical advice.
You complete an online medical intake (weight history, conditions, medications). A licensed clinician reviews it, typically within 24-48 hours, to decide whether compounded semaglutide or tirzepatide is appropriate. If approved, your first dose ships from a partner compounding pharmacy. Not everyone is eligible.
Treatment begins at the lowest titration dose. Appetite suppression and slower gastric emptying can start within the first 1-2 injections, but early weight change is usually small. Mild GI side effects (nausea, constipation with semaglutide; more diarrhea with tirzepatide) are most common now. Many people lose roughly 1-2% of body weight in the first month, but responses vary widely.
As your body adapts, the initial nausea and GI side effects typically ease for most people. Appetite suppression usually feels more consistent as drug levels stabilize. A provider checks in around dose-escalation points to confirm tolerance before stepping up.
Henry Meds uses a structured step-up schedule (commonly described as roughly 6 dose tiers over about 24 weeks), with provider review at each increase. Side effects can briefly return with each step up. Higher tiers add cost. Some people intentionally hold a lower dose longer if appetite control is already adequate; non-responders to semaglutide may switch to the tirzepatide pathway.
Weight loss tends to be most steady in this window once a maintenance dose is reached. In the STEP 1 trial, semaglutide patients lost about 2% of body weight per month for the first ~6 months. Individual results depend on dose, adherence, diet, and activity; many people lose less than trial averages.
Weight loss slows and eventually plateaus. Clinical trials show average total loss of roughly 15% at 68 weeks for semaglutide (STEP 1) and around 20% at 72 weeks for higher-dose tirzepatide (SURMOUNT-1) — these are trial averages, not guarantees. GLP-1 medications are generally intended for long-term use; stopping often leads to regain. Ongoing telehealth follow-up continues for monitoring and dose management.
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation, which are usually mild-to-moderate and worst during dose escalation. In STEP 1, about 4.5% of semaglutide users discontinued because of GI effects versus 0.8% on placebo. Serious but rarer risks include acute pancreatitis (severe abdominal pain), gallbladder disease, kidney injury from dehydration, and low blood sugar (especially when combined with other diabetes medications). All GLP-1 drugs in this class carry a boxed warning for thyroid C-cell tumors seen in rodents. The FDA has separately flagged compounded products for dosing errors and quality issues, including multiple adverse-event reports, some requiring hospitalization, tied to incorrect self-measured doses.
Sourced from FDA labeling and clinical references; not exhaustive and not a substitute for your prescriber or pharmacist. Always disclose every medication and supplement you take.
Starts at $297/mo from Henry Meds.
As of 2026, Henry Meds compounded injectable semaglutide runs roughly $297/month month-to-month, dropping to about $247/month on a 6-month plan and around $197/month on a 12-month prepay; oral and sublingual options are cheaper (often roughly $99-$249/month), and higher dose tiers typically add about $100/month (some tiers reach about $397/month). The price bundles provider visits, medication, and shipping with no separate membership fee. Compounded GLP-1s are essentially never covered by insurance and are paid out of pocket; by comparison, brand Wegovy or Zepbound can exceed $1,000/month without coverage. Note BBB complaints about auto-renewal billing, unexpected price increases, and refunds, so cancel before renewal and confirm current published pricing at signup.
Prices current as of May 29, 2026 and exclude promo codes; cash-pay and channel pricing change frequently — confirm with the pharmacy or provider.
If brand-name Wegovy or Zepbound is unaffordable or not covered, Henry Meds offers a markedly cheaper, real-prescriber route to the same drug classes. But you are trading FDA oversight, autoinjector convenience, and regulatory certainty for that price. Confirm current pricing and the legality of your specific prescription at signup, watch the auto-renewal billing closely, and discuss the trade-offs with your own physician before starting. This is general information, not medical advice.
Yes. Henry Meds is a legitimate US telehealth company (operating as Adonis Health Inc. since 2022) that uses licensed prescribers and compounding pharmacies, with no FDA warning letters to the company as of early 2026. However, it has an F Better Business Bureau rating tied to billing and cancellation complaints, so read the terms carefully before signing up.
No. Compounded semaglutide is not FDA-approved. It uses the same active ingredient as FDA-approved Wegovy and Ozempic, but compounded formulations do not undergo FDA pre-market review for safety, efficacy, or quality and may differ from the brand product.
As of 2026, compounded injectable semaglutide is roughly $297/month month-to-month, falling to about $247 on a 6-month plan and around $197 on a 12-month prepay; oral options are often cheaper. Higher dose tiers usually add about $100/month, and it is paid out of pocket since insurance rarely covers compounded drugs.
Only in limited circumstances. After the FDA declared the semaglutide shortage resolved in February 2025 (and tirzepatide in October 2024), mass compounding of copies became impermissible for 503A and 503B pharmacies. Legal supply now generally hinges on narrow patient-specific exceptions, such as a documented need for a dose or form not commercially available, which makes ongoing availability uncertain.
Henry Meds has no published trials of its own products. In the STEP 1 trial of the same active drug, 2.4 mg semaglutide produced an average 14.9% body-weight loss over 68 weeks, with tirzepatide producing larger average losses in its trials. Real-world results vary and may be lower with compounded or lower-strength formulations.
The most common are nausea, vomiting, diarrhea, and constipation, usually worst during dose increases. Rare but serious risks include pancreatitis and gallbladder disease, and the drug class carries a boxed warning for thyroid C-cell tumors. The FDA has also warned about dosing errors specific to compounded GLP-1 products, some requiring hospitalization.
Wegovy is FDA-approved, comes in a pre-filled autoinjector, and has full clinical-trial backing but costs $1,000+/month without insurance. Henry Meds is far cheaper and uses the same molecule, but it is compounded (not FDA-approved), often requires manual dosing, and faces regulatory uncertainty. Choose Wegovy if it is affordable or covered; consider Henry Meds mainly when brand access is not realistic, and discuss it with your doctor first.
No. Henry Meds operates on a cash-pay model, and compounded GLP-1 medications are essentially never reimbursed by insurance. The flat monthly price covers the provider visit, medication, and shipping, but you cannot bill it to insurance, and HSA/FSA eligibility is not guaranteed, so confirm with your plan administrator.
You can cancel, but a notable share of BBB complaints involve charges continuing after cancellation requests and difficulty getting refunds. Cancel before your renewal date, keep written confirmation, and review the auto-renewal and money-back-guarantee terms closely before signing up.
Affiliate link — we may earn a commission at no extra cost to you, and it never changes our rankings or score. Disclosure
Legitimate ways to lower your cost. We don’t sell Henry Meds GLP-1 — this is independent guidance, not medical or financial advice. Confirm current terms with the program and your clinician.
Many brand-name drugs have a manufacturer copay-savings program on the drug’s official site. Check the maker’s website for a current savings card (commercial insurance usually required; government insurance excluded).
If you’re uninsured or low-income, free or reduced-cost medication may be available through patient assistance programs. Search MedicineAssistanceTool (PhRMA) and NeedyMeds.
Filling a 90-day supply instead of monthly often lowers the per-month cost and cuts pharmacy trips. Ask your prescriber and pharmacy whether it’s an option for you.
A different formulation or product may cost less for a similar result. Compounded GLP-1 · Supplements vs GLP-1.
Same-category options, scored on the same six-axis rubric. Higher is better.